Experiment 67533
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | SOLARY,E: MANNONE,L: MOREAU,D: CAILLOT,D: CASASNOVAS,RO: GUY,H: GRANDJEAN,M: WOLF,JE: ANDRE,F: FENAUX,P: CANAL,P: CHAUFFERT,B: WOTAWA,A: BAYSSAS,M: GENNE,P:. (2000). PHASE I STUDY OF CINCHONINE, A MULTIDRUG RESISTANCE REVERSING AGENT, COMBINED WITH THE CHVP REGIMEN IN RELAPSED AND REFRACTORY LYMPHOPROLIFERATIVE SYNDROMES.. 4(12) |
| Amount utilized | |
| Compound isolated | |
| Disease | AN OPEN MULTICENTER, PHASE I TRIAL ENROLLED 34 PATIENTS WITHREFRACTORY LYMPHOPROLIFERATIVE SYNDROMES TO ASSESS THE MULTIDRUG RESISTANCE REVERSING EFFECT OF CINCHONINE. CINCHONINE DIHYDROCHLORIDE WAS ADMINISTERED BY CONTINUOUS I.V. INFUSION FOR 4 8H AND ESCALATED OVER FIVE DOSE LEVELS RANGING FROM 15 TO 35 MG/KG/D. CINCHONINE INFUSION STARTED 24H BEFORE AND LASTED FOR 24H THE MTD OF CINCHONINE ADMINISTERED BY CONTINUOUS I.V. INFUSION WAS 30 MG/KG/D. AN MDR REVERSING ACTIVITY WAS IDENTIFIED IN THE SERUM FROM EVERY PATIENT AND CORRELATED WITH CINCHONINE SERUM LEVEL. |
| Dose amount | 0.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | KG |
| Dose expression | LC50 |
| Gender | GIVEN TO BOTH SEXES |